Induction of Broadly Neutralising HCV Antibodies in Mice by Integration-deficient Lentiviral Vector-based Pseudotyped Particles

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Apr 30

PMID 23626846

Citations 13

Authors

Yao Deng

Jie Guan

Bo Wen

Na Zhu

Hong Chen

Jindong Song

Yang Yang

Yue Wang

Wenjie Tan

Affiliations

Soon will be listed here.

Abstract

Introduction: Integration-deficient lentiviral vectors (IDLVs) are a promising platform for immunisation to elicit both humoral immunity and cellular mediated immunity (CMI). Here, we compared the specific immunity in mice immunised via different regimens (homologous and cocktail) with IDLV-based HCV pseudoparticles (HCVpps) carrying pseudotyped glycoproteins E1E2 and bearing the HCV NS3 gene. Humoral and cell-mediated immune responses were also evaluated after IDLV-HCVpp immunisation combined with heterologous rAd5-CE1E2 priming protocols. Sera from the mice effectively elicited anti-E1, -E2, and -NS3 antibody responses, and neutralised various HCVpp subtypes (1a, 1b, 2a, 3a and 5a). No significant CMI was detected in the groups immunised with IDLV-based HCVpps. In contrast, the combination of rAd5-CE1E2 priming and IDLV-based HCVpp boosting induced significant CMI against multiple antigens (E1, E2, and NS3).

Conclusion: IDLV-based HCVpps are a promising vaccination platform and the combination of rAd5-CE1E2 and IDLV-based HCVpp prime-boost strategy should be further explored for the development of a cross-protective HCV vaccine.

Citing Articles

Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?.

Deng L, Liang P, Cui H Genes Dis. 2023; 10(5):1937-1955.

PMID: 37492721 PMC: 10363566. DOI: 10.1016/j.gendis.2022.03.007.

Lentiviral Vectors as a Vaccine Platform against Infectious Diseases.

Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L Pharmaceutics. 2023; 15(3).

PMID: 36986707 PMC: 10053212. DOI: 10.3390/pharmaceutics15030846.

Integrase deficient lentiviral vector: prospects for safe clinical applications.

Yew C, Gurumoorthy N, Nordin F, Tye G, Wan Kamarul Zaman W, Tan J PeerJ. 2022; 10:e13704.

PMID: 35979475 PMC: 9377332. DOI: 10.7717/peerj.13704.

Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through.

Gurumoorthy N, Nordin F, Tye G, Wan Kamarul Zaman W, Ng M Biomedicines. 2022; 10(1).

PMID: 35052787 PMC: 8773317. DOI: 10.3390/biomedicines10010107.

The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology.

Luis A Viruses. 2020; 12(10).

PMID: 33003492 PMC: 7600637. DOI: 10.3390/v12101103.

References

Bartosch B, Bukh J, Meunier J, Granier C, Engle R, Blackwelder W . In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A. 2003; 100(24):14199-204. PMC: 283569. DOI: 10.1073/pnas.2335981100. View

Meunier J, Engle R, Faulk K, Zhao M, Bartosch B, Alter H . Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A. 2005; 102(12):4560-5. PMC: 555507. DOI: 10.1073/pnas.0501275102. View

Pestka J, Zeisel M, Blaser E, Schurmann P, Bartosch B, Cosset F . Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007; 104(14):6025-30. PMC: 1851610. DOI: 10.1073/pnas.0607026104. View

Elmowalid G, Qiao M, Jeong S, Borg B, Baumert T, Sapp R . Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A. 2007; 104(20):8427-32. PMC: 1895966. DOI: 10.1073/pnas.0702162104. View

Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F . In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272(5259):263-7. DOI: 10.1126/science.272.5259.263. View

Yu M, Bartosch B, Zhang P, Guo Z, Renzi P, Shen L . Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A. 2004; 101(20):7705-10. PMC: 419670. DOI: 10.1073/pnas.0402458101. View

Garrone P, Fluckiger A, Mangeot P, Gauthier E, Dupeyrot-Lacas P, Mancip J . A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med. 2011; 3(94):94ra71. DOI: 10.1126/scitranslmed.3002330. View

Stamataki Z, Coates S, Evans M, Wininger M, Crawford K, Dong C . Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine. 2007; 25(45):7773-84. DOI: 10.1016/j.vaccine.2007.08.053. View

Zufferey R, Dull T, Mandel R, Bukovsky A, Quiroz D, Naldini L . Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998; 72(12):9873-80. PMC: 110499. DOI: 10.1128/JVI.72.12.9873-9880.1998. View

10.

Negri D, Michelini Z, Baroncelli S, Spada M, Vendetti S, Buffa V . Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther. 2007; 15(9):1716-23. DOI: 10.1038/sj.mt.6300241. View

11.

Karwacz K, Mukherjee S, Apolonia L, Blundell M, Bouma G, Escors D . Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol. 2009; 83(7):3094-103. PMC: 2655594. DOI: 10.1128/JVI.02519-08. View

12.

Strickland G, El-Kamary S, Klenerman P, Nicosia A . Hepatitis C vaccine: supply and demand. Lancet Infect Dis. 2008; 8(6):379-86. DOI: 10.1016/S1473-3099(08)70126-9. View

13.

Puig M, Major M, Mihalik K, Feinstone S . Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine. 2004; 22(8):991-1000. DOI: 10.1016/j.vaccine.2003.09.010. View

14.

Deng Y, Zhang K, Tan W, Wang Y, Chen H, Wu X . A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice. Vaccine. 2009; 27(15):2085-8. PMC: 7115398. DOI: 10.1016/j.vaccine.2009.02.003. View

15.

Zhang K, Tan W, Deng Y, Li J, Wu X, Ruan L . [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays]. Bing Du Xue Bao. 2008; 24(4):287-94. View

16.

Hu B, Tai A, Wang P . Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev. 2011; 239(1):45-61. PMC: 3030993. DOI: 10.1111/j.1600-065X.2010.00967.x. View

17.

Houghton M . Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev. 2011; 239(1):99-108. DOI: 10.1111/j.1600-065X.2010.00977.x. View

18.

Shimakami T, Lanford R, Lemon S . Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol. 2009; 9(5):537-44. PMC: 2782474. DOI: 10.1016/j.coph.2009.08.008. View

19.

Qi X, Gao Y, Lu R, Deng Y, Meng X, Tan W . [Peptide mapping of H-2d restricted T-cell epitope against six antigens of HIV-1 subtype B'/C by ELISPOT assay]. Bing Du Xue Bao. 2011; 27(1):34-43. View

20.

Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S . Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis. 2010; 202(6):862-6. PMC: 2931414. DOI: 10.1086/655902. View